Zevra Therapeutics Full Year 2024 Earnings: Revenues Beat Expectations, EPS Lags

Simply Wall St.03-13

Zevra Therapeutics (NASDAQ:ZVRA) Full Year 2024 Results

Key Financial Results

Revenue: US$23.6m (down 14% from FY 2023).
Net loss: US$105.5m (loss widened by 129% from FY 2023).
US$2.28 loss per share (further deteriorated from US$1.30 loss in FY 2023).

ZVRA Post-Clinical Trial Products

Approved (during full year): 1.
Launched (during full year): 1.

NasdaqGS:ZVRA Revenue and Expenses Breakdown March 13th 2025

All figures shown in the chart above are for the trailing 12 month (TTM) period

Zevra Therapeutics Revenues Beat Expectations, EPS Falls Short

Revenue exceeded analyst estimates by 15%. Earnings per share (EPS) missed analyst estimates by 17%.

In the last 12 months, the only revenue segment was Pharmaceuticals contributing US$23.6m. The largest operating expense was General & Administrative costs, amounting to US$54.9m (45% of total expenses). Explore how ZVRA's revenue and expenses shape its earnings.

Looking ahead, revenue is forecast to grow 37% p.a. on average during the next 3 years, compared to a 8.2% growth forecast for the Pharmaceuticals industry in the US.

Performance of the American Pharmaceuticals industry.

The company's shares are up 2.9% from a week ago.

Risk Analysis

It's still necessary to consider the ever-present spectre of investment risk. We've identified 2 warning signs with Zevra Therapeutics, and understanding them should be part of your investment process.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.